| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-020 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、可转债发行上市概况 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 15 日向不特定对象发行了 387.40 万张可转换公司债券，每张面值 100 元，发行总额 38,740.00 万元。发行方式采用向公司在股权登记日（2022 年 3 月 14 日，T-1 日）收市后登记在册的发行人原股东优先配售，原股东优先配售 后余额部分（含原股东放弃优先配售部分）通过上交所交易系统网上向社会公众 投资者发行，余额全部由保荐机构（主承销商）包销。 累计转股情况：上海阿拉丁生化科技股份有限公司（以下简称"公司"） 向不特定对象发行可转换公司债券"阿拉转债"自 2022 年 9 月 2 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][10]. Core Insights - The company has shown a steady increase in revenue and profitability, with a focus on expanding its product offerings and maintaining a competitive edge in the market [4][10]. - The company is positioned as a leading domestic research reagent provider, with significant growth potential driven by its brand and channel development [10][22]. Financial Performance - In Q4 2023, the company achieved a revenue of 120 million yuan, representing a year-on-year increase of 6.79% and a quarter-on-quarter increase of 23.40% [2]. - The net profit attributable to shareholders for Q4 2023 was 31 million yuan, up 14.35% year-on-year and 31.00% quarter-on-quarter [2]. - For the full year 2023, the company reported a total revenue of 403 million yuan, a 6.55% increase compared to the previous year, while the net profit attributable to shareholders decreased by 7.48% to 86 million yuan [5][10]. Product Segmentation - The high-end chemical segment generated 210 million yuan in revenue, a 14.72% increase year-on-year, while the life sciences segment saw a decline of 11.45% to 96 million yuan [6][27]. - The analytical chromatography segment reported a revenue of 52 million yuan, up 5.97% year-on-year, and the materials science segment increased by 29.06% to 32 million yuan [6][27]. Research and Development - The company invested 51 million yuan in R&D in 2023, marking a 31.56% increase from the previous year, focusing on specialized reagents and high-purity products [4][10]. - As of the end of 2023, the company had applied for 194 patents, with 132 granted, indicating a strong commitment to innovation [4][10]. Market Position and Strategy - The company is leveraging its brand and e-commerce capabilities to enhance sales, with its "Aladdin" brand recognized as a top choice in domestic reagent evaluations [22]. - The report highlights the potential for domestic substitution in the market, as the company aims to reduce reliance on foreign products [10][22].

Investment Rating - The report assigns a "Strong Buy" rating for the company, indicating that the stock is expected to outperform the market by more than 20% in the next six months [31]. Core Views - The company has shown steady revenue growth, with a reported revenue of 400 million yuan in 2023, representing a year-on-year increase of 6.6%. However, the net profit attributable to shareholders decreased by 7.5% to 86 million yuan [4][24]. - The acquisition of Yuan Ye Biological is expected to enhance the company's product line and drive future revenue growth, with projected revenue and profit increases of 25.9% and 44.2%, respectively, post-acquisition [6][29]. - The life sciences segment has experienced a decline in demand, while the high-end chemicals segment has achieved robust growth, with a revenue increase of 14.7% to 210 million yuan in 2023 [1][4]. Summary by Sections Financial Performance - The company reported a total revenue of 400 million yuan in 2023, with a net profit of 86 million yuan, reflecting a decrease of 7.5% year-on-year. The adjusted net profit was 83 million yuan, down 3.3% [4][24]. - Quarterly revenue showed a recovery trend, with Q1 to Q4 revenues of 90 million, 100 million, 100 million, and 120 million yuan, respectively [24]. Revenue Forecast - The company forecasts earnings per share (EPS) of 0.72 yuan, 0.92 yuan, and 1.15 yuan for 2024, 2025, and 2026, respectively [5][26]. - Revenue growth is expected to accelerate, with projected increases of 26% in 2024 and 23% in both 2025 and 2026 [26][29]. Segment Analysis - The high-end chemicals segment achieved a revenue of 210 million yuan in 2023, growing by 14.7%, while the life sciences segment saw a revenue of 96 million yuan, declining by 11% due to reduced industry demand [1][4]. - The experimental consumables segment reported a revenue of 8 million yuan, with a growth rate of 15% [1]. Acquisition Impact - The acquisition of Yuan Ye Biological for 181 million yuan is anticipated to broaden the product portfolio and enhance revenue streams, with a commitment from Yuan Ye to achieve a minimum of 33 million, 40 million, and 47 million yuan in net profit for 2024, 2025, and 2026, respectively [6][29].

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2024年3月28日、2024年3月29日 调研形式：线上交流 参与交流来访的机构投资者： 嘉实基金、易方达基金、富达基金(香港)有限公司、博时基金、国联基金、申 万宏源、中金公司、华宝基金、中泰证券、中信建投、西部证券、中信证券、 东北证券、永赢基金、浙商证券、东吴证券、华安证券、百年保险资产、北京 ...

Financial Performance - The company's operating revenue for 2023 was CNY 402.88 million, an increase of 6.55% compared to CNY 378.10 million in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY 85.83 million, a decrease of 7.48% from CNY 92.77 million in 2022[22]. - The basic earnings per share for 2023 was CNY 0.49, reflecting a 6.52% increase from CNY 0.46 in 2022[23]. - The company's total assets at the end of 2023 were CNY 1.51 billion, up 1.81% from CNY 1.48 billion at the end of 2022[22]. - The company's net assets attributable to shareholders increased by 6.32% to CNY 1.04 billion at the end of 2023, compared to CNY 974.80 million at the end of 2022[22]. - The company's comprehensive gross margin for 2023 is 60.20%, maintaining a high level historically[81]. - The company achieved operating revenue of CNY 402.88 million, a year-on-year increase of 6.55%[89]. - Net profit for the period was CNY 85.83 million, a decrease of 7.48% compared to the previous year[89]. Research and Development - Research and development expenses accounted for 12.72% of operating revenue in 2023, an increase of 2.42 percentage points from 10.30% in 2022[23]. - The company applied for 5 new patents during the reporting period, including 3 invention patents and 2 utility model patents[50]. - The number of R&D personnel increased to 187, representing 33.04% of the total workforce, up from 30.00% in the previous period[61]. - Total compensation for R&D personnel reached RMB 3,665.70 million, compared to RMB 2,847.63 million in the prior period, reflecting a significant increase[61]. - The company has developed over 3,200 analytical methods, enhancing its analysis capabilities with advanced instruments[64]. - R&D investment totaled ¥51,246,639.34, a year-on-year increase of 31.65%, accounting for 12.72% of operating income, up from 10.30%[54][55]. Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and senior management[131]. - There were no significant differences between the company's governance and the regulations set by the China Securities Regulatory Commission[131]. - The company has implemented various internal governance rules to ensure orderly management[131]. - The audit committee consists of Huang Zunshun, Lü Shunhui, and Jin Liyin, ensuring oversight of financial reporting[156]. - The remuneration and assessment committee includes Sun Jia, Huang Zunshun, and Gu Weiwei, focusing on executive compensation[157]. Risk Management - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company is exposed to safety production risks due to the hazardous nature of some of its chemical products[86]. - The company faces potential risks from macroeconomic fluctuations that could impact demand from its diverse downstream clients[85]. - The company has a risk of talent team construction inadequacy, which may hinder its ability to keep pace with industry developments[75]. - The company is at risk of core technology leakage due to reliance on a small number of key technical personnel[74]. Market Position and Strategy - The company focuses on the development of organic standards and standard solutions in the field of analytical chromatography, which are essential for quality analysis applications[37]. - The company operates an e-commerce platform (www.aladdin-e.com) for online sales, catering to diverse user needs in the research reagent sector[35]. - The company is recognized as a "Shanghai Enterprise Technology Center" and a "Demonstration Enterprise for Brand Cultivation" by local authorities, enhancing its reputation in the industry[34]. - The company is one of the most comprehensive manufacturers of research reagents in China, focusing on replacing imported products with its "Aladdin" brand[44]. - The company is actively involved in the development of high-end reagents, addressing significant market gaps and reducing reliance on imports[41]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[191]. - The chemical oxygen demand (COD) in wastewater was measured at 367 mg/L, below the standard limit of 500 mg/L[195]. - Total nitrogen in wastewater was recorded at 46.33 mg/L, under the limit of 70 mg/L[195]. - The company generated 41.334 tons of contaminated solid waste in 2023, with a year-end inventory of 3.581 tons[195]. - The company has implemented a comprehensive environmental monitoring plan, including wastewater, waste gas, and noise monitoring[199]. Shareholder Returns - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares, totaling approximately 59.44 million RMB, which represents 69.25% of the net profit attributable to shareholders for the year 2023[5]. - The company intends to increase its total share capital by 79.25 million shares through a capital reserve conversion, raising the total share capital to approximately 277.38 million shares[5]. - The company’s cash dividend policy emphasizes stable returns to investors while ensuring sustainable development[166].

本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-011 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 第四届监事会第十一次会议决议公告 本次会议由公司监事会主席姜苏先生主持，经全体监事表决，形成决议如下： (一) 审议通过《关于<2023 年度监事会工作报告>的议案》 经审议，公司监事会同意公司根据相关法律法规及公司章程的规定编制的 《2023 年度监事会工作报告》。 议案表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案需提交股东大会审议。 (二) 审议通过《关于<2023 年年度报告及其摘要>的议案》 经审议，公司监事会在全面了解和审核公司《2023 年年度报告及其摘要》 后，认为： （1）公司《2023 年年度报告及其摘要》编制和审核程序符合法律、法规、 《公司章程》和公司内部管理制度的各项规定； 一、监事会会议召开情况 上海阿拉丁生化科技股份有限 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-017 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于变更公司注册资本、修订《公司章程》并办理工 商登记和制定、修订部分治理制度的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日以现场结合通讯方式召开了公司第四届董事会第十八次会议（以下简称"本次 会议"），审议通过了《关于变更公司注册资本、修订<公司章程>并办理工商登记 的议案》《关于修订公司<独立董事工作制度>的议案》和《关于修订公司<董事会 审计委员会工作制度><董事会提名委员会工作制度><董事会薪酬与考核委员会 工作制度>并制定公司<独立董事专门会议工作制度>的议案》。现将有关情况公告 如下： 一、注册资本等变更情况 公司总股本为 141,520,391 股。具体内容详见公司于 2023 年 7 月 4 日刊登在上 ...

上海阿拉丁生化科技股份有限公司 董事会提名委员会工作制度 第三条 本工作制度所称的高级管理人员是指公司的总经理、副总经理、 财务总监、董事会秘书及《公司章程》中规定的其他高级管理人员。 第二章 人员组成 第四条 提名委员会成员由三名董事组成，独立董事占多数。 第五条 提名委员会委员由董事会从董事会成员中任命。 第六条 提名委员会设主任委员（召集人）一名，由独立董事委员担任， 负责主持提名委员会工作；召集人由董事会任命。 第七条 提名委员会与同届董事会任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根据 《公司章程》及本制度第四至第六条规定补足委员人数。 第三章 职责权限 第八条 提名委员会的主要职责权限： 第一章 总 则 第一条 为规范上海阿拉丁生化科技股份有限公司（以下简称"公司"） 董事和高级管理人员的产生，进一步完善公司治理结构，根据《中华人民共和国 公司法》及其它有关法律、法规、规范性文件及《上海阿拉丁生化科技股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，公司董事会特设立提名委员 会，并制定本工作制度。 第二条 提名委员会是董事会设立 ...

上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 作废 2021 年限制性股票激励计划 部分已授予尚未归属限制性股票的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 作废 2021 年限制性股票激励计划 部分已授予尚未归属限制性股票的 法律意见书 01F20216472 致：上海阿拉丁生化科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海阿拉丁生化科技股份有限公司 （以下简称"公司"或"阿拉丁"）的委托，并根据公司与本所签订的法律服务合同，作为公 司 2021 年限制性股票激励计划（以下简称"本次激励计划"）的法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则（2023 年 8 月修订）》（以下简称 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-018 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：本次关联交易属于上海阿拉丁生化科 技股份有限公司（以下简称"公司"）及全资子公司上海阿拉丁生物试剂有限公 司（以下简称"阿拉丁生物"）与关联方之间预计发生的日常关联交易，是正常 生产经营业务，以市场价格为定价依据，遵循平等自愿原则，交易风险可控，不 会对关联人形成较大的依赖，不影响公司的独立性，不存在损害公司及股东利益 的情况。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、独立董事专门会议审议情况 就本次日常关联交易预计事项，公司独立董事在董事会审议前召开了专门会 议，并一致审议通过了《关于 2024 年度日常关联交易预计 ...